The study involved 72 women with PCOS divided into two groups (liraglutide and placebo) in a 2:1 ratio. Measurements included baseline and 26-week follow-up assessments of bleeding pattern, levels of AMH, sex hormones, gonadotrophins, and ovarian morphology. This evidence concerns the gene AMH and polycystic ovary syndrome.